{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:45:02Z","timestamp":1785771902695,"version":"3.56.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"name":"INGEM grant"},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K02193"],"award-info":[{"award-number":["24K02193"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04930-9","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:44:42Z","timestamp":1785768282000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A rare variant in DPYD c.812delT causes severe adverse events of S-1 in a patient with tongue cancer"],"prefix":"10.1007","volume":"96","author":[{"given":"Hiroki","family":"Ishimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3240-9762","authenticated-orcid":false,"given":"Atsushi","family":"Suehiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8344-2469","authenticated-orcid":false,"given":"Daiki","family":"Hira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Hishinuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamitsu","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurie","family":"Katsube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Katada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuki","family":"Imayoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Shigetsura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsaku","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hiratsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"4930_CR1","doi-asserted-by":"publisher","first-page":"109066","DOI":"10.1016\/j.abb.2021.109066","volume":"714","author":"DC Forouzesh","year":"2021","unstructured":"Forouzesh DC, Moran GR (2021) Mammalian dihydropyrimidine dehydrogenase. Arch Biochem Biophys 714:109066. https:\/\/doi.org\/10.1016\/j.abb.2021.109066","journal-title":"Arch Biochem Biophys"},{"key":"4930_CR2","first-page":"4705","volume":"6","author":"AB van Kuilenburg","year":"2000","unstructured":"van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA et al (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6:4705\u20134712","journal-title":"Clin Cancer Res"},{"key":"4930_CR3","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/onco.13967","volume":"26","author":"BB Sharma","year":"2021","unstructured":"Sharma BB, Rai K, Blunt H, Zhao W, Tosteson TD, Brooks GA (2021) Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis. Oncologist 26:1008\u20131016. https:\/\/doi.org\/10.1002\/onco.13967","journal-title":"Oncologist"},{"key":"4930_CR4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ et al (2018) Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 Update. Clin Pharmacol Ther 103:210\u2013216. https:\/\/doi.org\/10.1002\/cpt.911","journal-title":"Clin Pharmacol Ther"},{"key":"4930_CR5","doi-asserted-by":"publisher","first-page":"930470","DOI":"10.3389\/fphar.2022.930470","volume":"13","author":"E Hishinuma","year":"2022","unstructured":"Hishinuma E, Narita Y, Obuchi K, Ueda A, Saito S, Tadaka S et al (2022) Importance of rare DPYD genetic polymorphisms for 5-Fluorouracil therapy in the Japanese population. Front Pharmacol 13:930470. https:\/\/doi.org\/10.3389\/fphar.2022.930470","journal-title":"Front Pharmacol"},{"key":"4930_CR6","unstructured":"The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT) (2024) Clinical use of pharmacogenetic tests: an official statement issued by The Japanese Society of Clinical Pharmacology and Therapeutics. https:\/\/www.jscpt.jp\/en\/press_release\/2107. Accessed 18 May 2026"},{"key":"4930_CR7","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1124\/dmd.118.081737","volume":"46","author":"E Hishinuma","year":"2018","unstructured":"Hishinuma E, Narita Y, Saito S, Maekawa M, Akai F, Nakanishi Y et al (2018) Functional characterization of 21 allelic variants of dihydropyrimidine dehydrogenase identified in 1070 Japanese individuals. Drug Metab Dispos 46:1083\u20131090. https:\/\/doi.org\/10.1124\/dmd.118.081737","journal-title":"Drug Metab Dispos"},{"key":"4930_CR8","doi-asserted-by":"publisher","first-page":"e2300599","DOI":"10.1200\/PO.23.00599","volume":"8","author":"ABP van Kuilenburg","year":"2024","unstructured":"van Kuilenburg ABP, Pleunis-van Empel MCH, Brouwer RB, Sijben AEJ, Knapen DG, Oude Munnink TH et al (2024) Lethal capecitabine toxicity in patients with complete dihydropyrimidine dehydrogenase deficiency due to ultra-rare DPYD variants. JCO Precis Oncol 8:e2300599. https:\/\/doi.org\/10.1200\/PO.23.00599","journal-title":"JCO Precis Oncol"},{"key":"4930_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/annonc\/mdg056","volume":"14","author":"ABP van Kuilenburg","year":"2003","unstructured":"van Kuilenburg ABP, Baars JW, Meinsma R, van Gennip AH (2003) Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene. Ann Oncol 14:341\u2013342. https:\/\/doi.org\/10.1093\/annonc\/mdg056","journal-title":"Ann Oncol"},{"key":"4930_CR10","doi-asserted-by":"publisher","first-page":"5150725","DOI":"10.1155\/2019\/5150725","volume":"2019","author":"N Bukhari","year":"2019","unstructured":"Bukhari N, Azam F, Alfawaz M, Zahrani M (2019) Identifying a novel DPYD polymorphism associated with severe toxicity to 5-FU chemotherapy in a saudi patient. Case Rep Genet 2019:5150725. https:\/\/doi.org\/10.1155\/2019\/5150725","journal-title":"Case Rep Genet"},{"key":"4930_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.mayocp.2013.09.008","volume":"89","author":"MW Saif","year":"2014","unstructured":"Saif MW, Lee AM, Offer SM, McConnell K, Relias V, Diasio RB (2014) A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach. Mayo Clin Proc 89:131\u2013136. https:\/\/doi.org\/10.1016\/j.mayocp.2013.09.008","journal-title":"Mayo Clin Proc"},{"key":"4930_CR12","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/1535-7163.MCT-13-0878","volume":"13","author":"SM Offer","year":"2014","unstructured":"Offer SM, Butterfield GL, Jerde CR, Fossum CC, Wegner NJ, Diasio RB (2014) microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. Mol Cancer Ther 13:742\u2013751. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0878","journal-title":"Mol Cancer Ther"},{"key":"4930_CR13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00280-009-1071-0","volume":"65","author":"J Fidlerova","year":"2010","unstructured":"Fidlerova J, Kleiblova P, Bilek M, Kormunda S, Formankova Z, Novotny J et al (2010) Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients. Cancer Chemother Pharmacol 65:661\u2013669. https:\/\/doi.org\/10.1007\/s00280-009-1071-0","journal-title":"Cancer Chemother Pharmacol"},{"key":"4930_CR14","first-page":"4409","volume":"6","author":"K Ikeda","year":"2000","unstructured":"Ikeda K, Yoshisue K, Matsushima E, Nagayama S, Kobayashi K, Tyson CA et al (2000) Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res 6:4409\u20134415","journal-title":"Clin Cancer Res"},{"key":"4930_CR15","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/bjc.2017.94","volume":"116","author":"D Meulendijks","year":"2017","unstructured":"Meulendijks D, Henricks LM, Jacobs BAW, Aliev A, Deenen MJ, de Vries N et al (2017) Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer 116:1415\u20131424. https:\/\/doi.org\/10.1038\/bjc.2017.94","journal-title":"Br J Cancer"},{"key":"4930_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","volume":"249","author":"M Boisdron-Celle","year":"2007","unstructured":"Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A et al (2007) 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 249:271\u2013282. https:\/\/doi.org\/10.1016\/j.canlet.2006.09.006","journal-title":"Cancer Lett"},{"key":"4930_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/s1040-8428(98)00036-5","volume":"30","author":"E Gamelin","year":"1999","unstructured":"Gamelin E, Boisdron-Celle M (1999) Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer\u2013status of the art. Crit Rev Oncol Hematol 30:71\u201379. https:\/\/doi.org\/10.1016\/s1040-8428(98)00036-5","journal-title":"Crit Rev Oncol Hematol"},{"key":"4930_CR18","doi-asserted-by":"publisher","first-page":"100125","DOI":"10.1016\/j.esmoop.2021.100125","volume":"6","author":"K Hodroj","year":"2021","unstructured":"Hodroj K, Barthelemy D, Lega JC, Grenet G, Gagnieu MC, Walter T et al (2021) Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature. ESMO Open 6:100125. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100125","journal-title":"ESMO Open"},{"key":"4930_CR19","first-page":"617","volume":"33","author":"A Itoi","year":"2006","unstructured":"Itoi A, Takashima M, Ishimasa H, Murata H, Tomoda K (2006) [Adjuvant chemotherapy with TS-1 for head and neck cancer-side effect of two-week application followed by one-week rest regimen]. Gan Kagaku Ryoho 33:617\u2013620","journal-title":"Gan Kagaku Ryoho"},{"key":"4930_CR20","unstructured":"Okayama Taiho Pharmaceutical Co., Ltd (2025) TS-1 combination OD tablets T20 package insert [in Japanese]. Pharmaceuticals and Medical Devices Agency (PMDA). https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/340264_4229101F1050_1_08. Accessed 21 May 2025"},{"key":"4930_CR21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/s0065-2571(00)00011-x","volume":"41","author":"MR Johnson","year":"2001","unstructured":"Johnson MR, Diasio RB (2001) Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 41:151\u2013157. https:\/\/doi.org\/10.1016\/s0065-2571(00)00011-x","journal-title":"Adv Enzyme Regul"},{"key":"4930_CR22","unstructured":"Tohoku Medical Megabank Organization (n d.) Short read (SR) small variant (SNV+INDEL) viewer. https:\/\/jmorp.megabank.tohoku.ac.jp\/genome-variations\/sr-snvindel\/00ae93b8e10a20000. Accessed 20 May 2025"},{"key":"4930_CR23","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3390\/jcm9082342","volume":"9","author":"E Hishinuma","year":"2020","unstructured":"Hishinuma E, Guti\u00e9rrez Rico E, Hiratsuka M (2020) In vitro assessment of fluoropyrimidine-metabolizing enzymes: dihydropyrimidine dehydrogenase, dihydropyrimidinase, and \u03b2-ureidopropionase. J Clin Med 9:2342. https:\/\/doi.org\/10.3390\/jcm9082342","journal-title":"J Clin Med"},{"key":"4930_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bbapap.2004.06.009","volume":"1701","author":"KD Schnackerz","year":"2004","unstructured":"Schnackerz KD, Dobritzsch D, Lindqvist Y, Cook PF (2004) Dihydropyrimidine dehydrogenase: a flavoprotein with four iron-sulfur clusters. Biochim Biophys Acta 1701:61\u201374. https:\/\/doi.org\/10.1016\/j.bbapap.2004.06.009","journal-title":"Biochim Biophys Acta"},{"key":"4930_CR25","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1158\/0008-5472.CAN-13-2482","volume":"74","author":"SM Offer","year":"2014","unstructured":"Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB (2014) Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res 74:2545\u20132554. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2482","journal-title":"Cancer Res"},{"key":"4930_CR26","unstructured":"Tohoku Medical Megabank Organization (n d.) Short read (SR) small variant (SNV+INDEL) viewer. https:\/\/jmorp.megabank.tohoku.ac.jp\/genome-variations\/sr-snvindel\/00ae7fc9f88e80000. Accessed 20 May 2025"},{"key":"4930_CR27","unstructured":"Tohoku Medical Megabank Organization (n d.) Short read (SR) small variant (SNV+INDEL) viewer. https:\/\/jmorp.megabank.tohoku.ac.jp\/genome-variations\/sr-snvindel\/09869905f08e80000. Accessed 20 May 2025"},{"key":"4930_CR28","unstructured":"Tohoku Medical Megabank Organization (n d.) Short read (SR) small variant (SNV+INDEL) viewer. https:\/\/jmorp.megabank.tohoku.ac.jp\/genome-variations\/sr-snvindel\/0431d04f488900000. Accessed 20 May 2025"},{"key":"4930_CR29","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/bcp.13007","volume":"82","author":"BA Jacobs","year":"2016","unstructured":"Jacobs BA, Deenen MJ, Pluim D, van Hasselt JG, Kr\u00e4henb\u00fchl MD, van Geel RM et al (2016) Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers. Br J Clin Pharmacol 82:706\u2013716. https:\/\/doi.org\/10.1111\/bcp.13007","journal-title":"Br J Clin Pharmacol"},{"key":"4930_CR30","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/cpt.2069","volume":"109","author":"JE Knikman","year":"2021","unstructured":"Knikman JE, Gelderblom H, Beijnen JH, Cats A, Guchelaar HJ, Henricks LM (2021) Individualized dosing of fluoropyrimidine-based chemotherapy to prevent severe fluoropyrimidine-related toxicity: what are the options? Clin Pharmacol Ther 109:591\u2013604. https:\/\/doi.org\/10.1002\/cpt.2069","journal-title":"Clin Pharmacol Ther"},{"key":"4930_CR31","unstructured":"Tohoku Medical Megabank Organization (n d.) Short read (SR) copy number variant (CNV) viewer. https:\/\/jmorp.megabank.tohoku.ac.jp\/genome-variations\/sr-cnv\/hg38-chr19-40844300?srSnvindelTranscriptId=NM_000762.6. Accessed 20 May 2025"},{"key":"4930_CR32","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/sj.clpt.6100484","volume":"83","author":"Y Kaida","year":"2008","unstructured":"Kaida Y, Inui N, Suda T, Nakamura H, Watanabe H, Chida K (2008) The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer. Clin Pharmacol Ther 83:589\u2013594. https:\/\/doi.org\/10.1038\/sj.clpt.6100484","journal-title":"Clin Pharmacol Ther"},{"key":"4930_CR33","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1200\/JCO.2013.51.1857","volume":"32","author":"D Rosmarin","year":"2014","unstructured":"Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E et al (2014) Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 32:1031\u20131039. https:\/\/doi.org\/10.1200\/JCO.2013.51.1857","journal-title":"J Clin Oncol"},{"key":"4930_CR34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00280-017-3478-3","volume":"81","author":"NA Nahid","year":"2018","unstructured":"Nahid NA, Apu MNH, Islam MR, Shabnaz S, Chowdhury SM, Ahmed MU et al (2018) DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer. Cancer Chemother Pharmacol 81:119\u2013111. https:\/\/doi.org\/10.1007\/s00280-017-3478-3","journal-title":"Cancer Chemother Pharmacol"},{"key":"4930_CR35","doi-asserted-by":"publisher","first-page":"1184523","DOI":"10.3389\/fphar.2023.1184523","volume":"14","author":"A Maslarinou","year":"2023","unstructured":"Maslarinou A, Manolopoulos VG, Ragia G (2023) Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm? Front Pharmacol 14:1184523. https:\/\/doi.org\/10.3389\/fphar.2023.1184523","journal-title":"Front Pharmacol"},{"key":"4930_CR36","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","volume":"40","author":"ABP van Kuilenburg","year":"2004","unstructured":"van Kuilenburg ABP (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40:939\u2013950. https:\/\/doi.org\/10.1016\/j.ejca.2003.12.004","journal-title":"Eur J Cancer"},{"key":"4930_CR37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/00008571-200004000-00002","volume":"10","author":"ES Collie-Duguid","year":"2000","unstructured":"Collie-Duguid ES, Etienne MC, Milano G, McLeod HL (2000) Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 10:217\u2013223. https:\/\/doi.org\/10.1097\/00008571-200004000-00002","journal-title":"Pharmacogenetics"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04930-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04930-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04930-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:44:43Z","timestamp":1785768283000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04930-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4930"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04930-9","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest associated with this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was waived for this single case report.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Verbal informed consent for the pharmacogenomic analyses and the publication of this case report was obtained from the patient, and documented in the electronic medical record. Oral consent for publication of this case report was obtained from the patient, and this consent was documented in the medical record.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"83"}}